Advertisement
Sino Biological
Sino Biological

BioMed Central sold to Springer

The world's largest open access publisher, BioMed Central, has been sold to Springer. BioMed Central (a former sister company of The Scientist) publishes 180 peer-reviewed journals under the open access publishing model, meaning that anyone can read articles for free once they are published, and authors pay a per-page fee to publish in the journals. There are no plans to change the journal publishing costs or fees, Matt McKay, director of public relations at BioMed Central, told The Scientist.

By | October 7, 2008

The world's largest open access publisher, BioMed Central, has been sold to Springer. BioMed Central (a former sister company of The Scientist) publishes 180 peer-reviewed journals under the open access publishing model, meaning that anyone can read articles for free once they are published, and authors pay a per-page fee to publish in the journals. There are no plans to change the journal publishing costs or fees, Matt McKay, director of public relations at BioMed Central, told The Scientist. "There are no plans to change the publishing model, as part of the terms and conditions of the agreement of the board of trustees," McKay added. "We are committed to open access and the open access publishing model remains the same." Springer publishes 1,700 journals in science, technology, and medicine, and is one of three publishing groups that has a green open access policy; authors can pay a processing fee of $3000, and the article becomes immediately open access upon publication. Springer publishes the journal of Microbial Ecology and Functional & Integrative Genomics. Last year, linkurl:Yale University dropped;http://www.the-scientist.com/news/display/53450/ its subscription to BioMed Central, citing the rising costs to the university. Flat fees for membership can cost around $30,000 a year. BioMed Central publisher Matt Cockerill sent an Email to the BioMed journal editors informing them of the acquisition, Scientific American linkurl:reported.;http://www.sciam.com/blog/60-second-science/post.cfm?id=open-access-publisher-biomed-centra-2008-10-07 Everything "is 'business as usual' for all BioMed Central staff and journals," he wrote. McKay declined to say how much Springer paid for the acquisition. In a linkurl:statement;https://mx2.arl.org/Lists/SPARC-OAForum/Message/4605.html from Springer, CEO of Science and Business Media Derk Haank said: "This acquisition reinforces the fact that we see open access publishing as a sustainable part of [scientific, technical, and medical] publishing, and not an ideological crusade."
Advertisement

Comments

Avatar of: anonymous poster

anonymous poster

Posts: 1

October 7, 2008

I'm curious, since BioMed Central has just been sold, does that mean The Scientist will be sold as well?

October 7, 2008

The sale of BioMed Central doesn't have any impact on The Scientist. The two companies were run separately despite being part of the same group.\n
Avatar of: ERIC J MURPHY

ERIC J MURPHY

Posts: 18

October 7, 2008

This brings up a real issue with regards to consolidation of the science publishing industry. The question is when will we be moving to a "one world order" in the area, commonly referred to as a monopoly? \n\nThe problem will be that we will face limited choices with regard to policies and such as more and more journals come under one of two major publishing houses. \n\nWhile I don't agree with the BioMed Central model, I thought it was an interesting experiment. The question is how long will Springer keep this model? \n\nAs for The Scientist, no worries there at all. In fact, this is probably a good move from that point of view.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Mettler Toledo
BD Biosciences
BD Biosciences